Core Insights - Caribou Biosciences is advancing its clinical programs for hematologic malignancies and autoimmune diseases, with two key clinical data disclosures expected in the first half of 2025 [2][11] - The company reported a cash position of $249.4 million as of December 31, 2024, which is projected to fund operations into the second half of 2026 [12][20] Clinical Programs - CB-010 is an allogeneic anti-CD19 CAR-T cell therapy being evaluated in the ANTLER Phase 1 trial for second-line large B cell lymphoma and in the GALLOP Phase 1 trial for lupus nephritis [3][4][17] - CB-011 is an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma, currently in the CaMMouflage Phase 1 trial [5][18] - CB-012 is an allogeneic anti-CLL-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, undergoing the AMpLify Phase 1 trial [6][19] Financial Performance - Licensing and collaboration revenue for Q4 2024 was $2.1 million, down from $3.6 million in Q4 2023, with full-year revenue of $10.0 million compared to $34.5 million in 2023 [13] - Research and development expenses increased to $30.5 million for Q4 2024 and $130.2 million for the full year, compared to $31.3 million and $112.1 million in the previous year [14] - General and administrative expenses rose to $10.5 million for Q4 2024 and $46.5 million for the full year, compared to $9.7 million and $38.5 million in 2023 [15] Corporate Updates - Sri Ryali was appointed as the new Chief Financial Officer in January 2025, overseeing finance, investor relations, and corporate communications [9] - Chief Scientific Officer Steve Kanner will retire in June 2025 after nearly eight years, transitioning to an advisory role [10] Anticipated Milestones - Caribou plans to present data from the ANTLER and CaMMouflage trials in H1 2025, with a pivotal Phase 3 trial for CB-010 expected to start in H2 2025 if initial data supports it [11][15][22]

Core Viewpoint - A class action securities lawsuit has been filed against Caribou Biosciences, Inc. alleging securities fraud that affected investors between July 14, 2023, and July 16, 2024 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Caribou Biosciences overstated the safety, efficacy, and durability of its product CB-010 compared to approved CAR-T cell therapies for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL) [2]. - It is alleged that Caribou was at significant risk of having insufficient cash and liquidity to fund its business operations, including preclinical research for its allogeneic CAR-NK platform [2]. - The lawsuit suggests that these issues were likely to have a significant negative impact on Caribou's business and operations, rendering the defendants' public statements materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 24, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Caribou Biosciences, Inc. regarding a class action lawsuit due to alleged misleading statements and financial risks associated with the company's product CB-010 [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from July 14, 2023, to July 16, 2024 [2]. - Allegations include that Caribou overstated the safety, efficacy, and durability of CB-010 compared to approved therapies, and failed to disclose significant risks regarding cash and liquidity [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by February 24, 2025, to potentially become lead plaintiffs [3]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that inflated the company's stock [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Caribou Biosciences, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's product safety and financial stability [2][4]. Group 1: Allegations Against Caribou - The complaint alleges that Caribou overstated the safety, efficacy, and durability of its product CB-010 compared to approved therapies [4]. - It is claimed that Caribou was at significant risk of insufficient cash and liquidity to fund its operations, including preclinical research [4]. - The allegations suggest that these issues could have a significant negative impact on Caribou's business and operations [4]. Group 2: Stock Performance and Analyst Reactions - Following the announcement of updated clinical data on June 2, 2024, Caribou's stock was downgraded by Evercore ISI, with a price target reduction from $13.00 to $3.00 [5]. - On June 3, 2024, Caribou's stock price fell by $0.735, or 25.52%, closing at $2.145 per share [6]. - After disclosing workforce reductions and the discontinuation of preclinical research on July 16, 2024, the stock price fell by $0.09, or 3.3%, to close at $2.64 per share on July 17, 2024 [7]. Group 3: Legal Proceedings and Class Action - Investors who suffered losses exceeding $75,000 between July 14, 2023, and July 16, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1]. - There is a deadline of February 24, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against Caribou [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [8].

Core Viewpoint - A class action securities lawsuit has been filed against Caribou Biosciences, Inc. alleging securities fraud that affected investors between July 14, 2023, and July 16, 2024 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Caribou Biosciences overstated the safety, efficacy, and durability of its product CB-010 compared to approved CAR-T cell therapies for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL) [2]. - It is alleged that Caribou faced significant risks regarding insufficient cash and liquidity to fund its business operations, including preclinical research for its allogeneic CAR-NK platform [2]. - The lawsuit suggests that these issues were likely to have a substantial negative impact on Caribou's business and operations, rendering the defendants' public statements materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 24, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Caribou Biosciences, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its business operations and the viability of its product CB-010 during the specified class period [1][3]. Group 1: Class Action Details - The class action represents investors who purchased securities between July 14, 2023, and July 16, 2024, with a deadline of February 24, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Allegations Against Caribou - The complaint claims that Caribou exaggerated the safety, effectiveness, and long-term viability of CB-010 compared to existing CAR-T cell therapies for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL) [3]. - It is alleged that Caribou faced significant risks regarding cash, liquidity, and capital necessary for ongoing business operations, including preclinical research related to its allogeneic CAR-NK platform [3]. - The issues raised in the complaint are expected to severely impact Caribou's business and operations, rendering the defendants' public statements materially false and misleading throughout the class period [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Caribou Biosciences, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Caribou securities is from July 14, 2023, to July 16, 2024, and the lead plaintiff deadline is February 24, 2025 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]. Group 3: Case Allegations - The lawsuit alleges that Caribou made false and misleading statements regarding the safety, efficacy, and commercial prospects of its product CB-010, particularly in comparison to approved therapies [4]. - It is claimed that Caribou was at significant risk of insufficient cash and liquidity to fund its operations, which could negatively impact its business [4]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, leading to investor damages when the truth was revealed [4].

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Caribou Biosciences, Inc. regarding a class action lawsuit due to alleged misleading statements and financial risks associated with the company's product CB-010 [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from July 14, 2023, to July 16, 2024 [2]. - Allegations include that Caribou overstated the safety, efficacy, and durability of CB-010 compared to approved therapies, and failed to disclose significant risks regarding cash and liquidity [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by February 24, 2025, to potentially become lead plaintiffs [3]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...